• Skip to main content
  • Skip to secondary menu
  • Skip to footer

Press Media Release

press release distribution

  • Sponsored Post
  • Market Wire
  • About
    • Template for press/media release
    • How to structure your press release for maximum impact
    • Crafting effective headlines and leads to capture journalists’ attention
    • Understanding the dos and don’ts of writing press releases
    • Tips for writing clear, concise, and informative press releases
    • The importance of understanding your audience before writing a press release
    • Best practices for incorporating quotes and statistics in your press release
    • Writing effective boilerplates and about us sections for press releases
    • Identifying key media contacts and building relationships with journalists
    • Writing for different types of media, such as print, online, and social media
    • Measuring the success of your press release and tracking media coverage
  • Contact
    • GDPR

Statement from Sarah Yim, M.D., acting director of the Office of Therapeutic Biologics and Biosimilars in the FDA’s Center for Drug Evaluation and Research, on FDA’s continued progress facilitating competition in the biologic marketplace with approval of 25th biosimilar product

November 16, 2019 By admin

Biological products play an increasingly central role in modern medicine, offering treatments for many serious illnesses. Commonly referred to as biologics, these medicines are generally made from natural or living sources, like animal and plant cells, and microorganisms such as bacteria or yeast, and developed using advanced science. They are usually more complex than other drugs and are particularly critical in the treatment of cancer and autoimmune conditions, such as rheumatoid arthritis, psoriasis and inflammatory bowel disease.

Historically, biologics lacked effective competition in the marketplace because there was no abbreviated FDA review pathway for bringing “follow-on” versions of biologics to market. That changed when Congress gave FDA the authority to implement an abbreviated approval pathway for biosimilar and interchangeable biological products in 2010. This pathway provides for the agency’s review and approval of biosimilar products, which may offer more access to treatments and lower costs for patients. A biosimilar product is highly similar to, and has no clinically meaningful differences from, an existing FDA-approved biologic product, called the reference product. Our ability to support a market for safe, effective biosimilar products is key for patients and our nation’s health care system.

Today the FDA took another step to further foster biologics competition with the approval of Abrilada (adalimumab – afzb), a biosimilar to Humira. Today’s approval is one of nine new biosimilar products the FDA has taken action on in 2019, bringing the overall total of biosimilar approvals to 25. I’m pleased to see this progress and am confident that the market for these therapies will continue to grow. To date, 74 programs for 38 different reference products have been enrolled in our Biosimilar Product Development Program to discuss development of proposed biosimilar products or interchangeable products, laying the foundation for ongoing competition in the marketplace.

Importantly, health care professionals and patients can be confident when using an FDA-approved biosimilar product. Biosimilar products approved by the FDA undergo a rigorous evaluation to determine that they meet the requirements for licensure and are manufactured under the same quality standards as brand name medicines.

We are also continuing the agency’s work under the Biosimilars Action Plan to improve the efficiency of the biosimilar and interchangeable product development and approval process. This includes efforts to develop and implement new biosimilar-specific review templates and progress towards the development and validation of pharmacodynamic biomarkers tailored to biosimilar development. As outlined in this plan, we’re continuing to provide scientific and regulatory clarity for the biosimilar development community, and at the same time, we are undertaking communication and outreach efforts for educating patients, clinicians and payors about biosimilars’ safety and effectiveness.

Another important part of our work, at Congress’ direction, is facilitating the March 23, 2020, transition of approved marketing applications for biological products regulated under the Federal Food, Drug, and Cosmetic Act to be approved biologics license applications regulated under the Public Health Service Act (PHS Act). This means that these biological products, including products like insulin that are in great demand and have seen price increases, will be regulated under the PHS Act like other biological products and open to biosimilar competition. This, in turn, could lead to the development of more affordable biosimilar insulin products, including products that are interchangeable with branded insulins, without any compromise in safety and effectiveness. The FDA held a public hearing on the development of biosimilar and interchangeable insulin products in May, and we are analyzing the comments we received from many different stakeholders, including those who are directly affected by the price of insulin and who would benefit from the impact of additional competition from biosimilar and interchangeable products. Our work in this area continues and is a high priority.

The promise of biosimilar and interchangeable biological products in providing increased access to important therapies is great, and the FDA will continue to do all that we can to facilitate competition in this area.

The FDA granted the approval of Abrilada to Pfizer Inc. Humira was approved in December 2002 and is manufactured by AbbVie Inc.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation and for regulating tobacco products.

SOURCE U.S. Food and Drug Administration
http://www.fda.gov

Filed Under: Press Release Tagged With: Biosimilars, Center for Drug Evaluation and Research, FDA, Office of Therapeutic Biologics and Biosimilars, Sarah Yim, Therapeutic Biologics

Footer

Recent Posts

  • Quectel Launches SP900BF-AP Edge AI Module With 100 TOPS and Ten 5G Combo Antennas at electronica 2026
  • Drax, Brookfield and Radiant Announce a 20 Billion Pound AI Data Centre With No Tenant, No Power Price and No Planning Consent Yet
  • Deal Releases November 5 2026 GE HealthCare Leads Up to 160 Million Dollars for Laza Medical and Priority Software Buys Fireberry
  • Tech Press Release Digest November 5 2026 Renesas Puts a Robot Controller on One Chip and Mirth Connect 4.8 Ships
  • A. O. Smith Sells 81 Percent of Its China Business to CPE at a Valuation Below One Year of Sales
  • Tokening, EByte, and Posterial Give Recent Project Updates Somewhere Useful to Lead
  • Press Releases Need Evidence Beyond a Strong Headline
  • School Communications Become an Enrollment Strategy, With AI Joining the Toolkit
  • Tech Press Release Digest: Record $425B Chip Quarter, Claude for Financial Advisors and Temporal’s $550M Raise
  • Japan Lost Its Export Lead to South Korea and Taiwan. AI Chips Explain Almost All of It

Media Partners

  • Press Club US
  • ZGM.org
  • Referently.com
Czech Television and Czech Radio Strike for a Day as Babiš Moves Public Media Onto the State Budget
Trump Says He May Move the White House Press Corps Out of the Brady Briefing Room
CrossGov.com Gives Reporters Covering Washington a Ready Story List: Tariff Refunds, a Shrinking CISA, FEMA Denials and an IRS With No Commissioner
Why Social Unrest Has Become a Standing Condition in Europe and the United States
UN Secretary-General Race: Rodrigues Birkett Takes the Lead While Grossi Collects Discourage Votes
Eight Pulitzer Winners and Finalists Used AI in Their 2026 Work
BuzzFeed and GB News Cut a Third of Staff Each as 2026 Job Losses Pile Up
Hormuz Talks Stall, Samsung Stacks Memory on the GPU, Taiwan Slows Its Own Networks: August 10 Briefing
Trump Administration Clears Saudi Nuclear Deal Without Enrichment Safeguards
Lindsey Graham, South Carolina Senator and Foreign Policy Hawk, Dies at 71
The Legend of Zelda Ocarina of Time Remake Sells Over 5 Million on Switch 2 in Four Days as Nintendo Builds Toward the 2027 Film
Hackers Turned Supermarket Freezers Into Heaters Across Europe and the Weak Point Was the Remote Maintenance Link
Tablet Shipments Fall 23 Percent to 32 Million in Q3 2026 and Only Lenovo Grows Among the Top Five
Vertiv Packages AI Rack Power and Cooling for Existing Facilities
Posterial, HomePremise, and RefurbishedContainers Turn Visual Concepts Into Editorial Projects
CrossGov.com Reads Washington for Market Signals: Section 232 Tariffs, Data Centre Grid Fights, LNG Approvals and a 4% Fed
Mid-September Across the Network: Chokepoints, Memory Prices, and the Crawler Block Landing September 15
YouTube's Creator Partnerships API Turns Influencer Deals Into Programmatic Media Buys
Scripps Cuts 268 Jobs and Rebuilds Local TV News Around Automation
Singapore's GDP Upgrade and CoreWeave's $104 Billion Backlog: The AI Boom Has Reached the Lagging Indicators
Isolated Gate Driver Explained, What It Does in Inverters, Chargers and Motor Drives
Cohort Stock Decline Explained, Why Themed Stocks Fall Together and When the Selling Ends
Force Majeure
Why Database Indexes Make Some Queries Faster and Writes More Expensive
High-Frequency Trading Explained: Speed, Strategies and the Structure of Modern Markets
Stirling Engines Explained From Working Gas to Useful Power
CoWoS Explained: TSMC's Advanced Packaging and Why It Bottlenecks AI Chips
Stock Market Circuit Breakers Explained: Market-Wide Halts, LULD Bands and Single-Stock Pauses
Short Interest Explained: Days to Cover, Percent of Float and How Short Squeezes Start
Rare Earth Magnet Supply Chain Explained: Mining, Separation, NdFeB Magnets and China's Hold on Each Step

Media Partners

  • Media Presser
  • 3V.org
  • k4i.com
Pulley Raises 64 Million Dollars as Permitting Delays Hold Back Construction
MarketAnalysis Digest, November 18 2026, Nvidia Margins, AI Export Controls and Hormuz Risk
Omdia Counts a 23% Drop in Q3 2026 Tablet Shipments as Lenovo Finds Only 10% of IT Leaders Rebuilt the Workplace for AI
Nielsen Prices 1.4 Billion Dollars of 10.5 Percent Notes to Pay for DoubleVerify and Puts Ad Verification on Private Equity Debt
Bank of England, Czech National Bank and Bank of Canada Raise Rates as an Energy Shock Feeds Inflation
Media Earnings November 5 2026 Nexstar Posts a Record 2.1 Billion Dollars and IMAX Nearly Doubles Its Box Office Record
FuriosaAI, Serval and Solink Lead Over a Billion Dollars of AI Funding in One Day
News Embargoes Break Because the Incentives Do, and the Fix Is Fewer Embargoes
RenderCache, EByte, and Selectivity Expose the Limits Behind a Successful Software Result
Q3 2026 Bank Earnings Show Net Interest Income Growing Again Just as the Fed Turns to Hikes
Torus Raises $500 Million to Put AI Inference Next to Spare Grid Capacity With Foundry
OpenAI Banks 11 Billion Dollars at a Trillion-Plus Valuation After Cutting Its Round From 30 Billion to 20
Deal Digest November 5 2026 Five9 Pays 325 Million Dollars for Level AI and MasTec Drops a Deal to Buy Back Stock
Deal Digest October 29 2026 DoorDash Buys Instacart for 17 Billion Dollars and Xerox Pays More to Owe Less
SK Hynix Says Memory Stays Short Through 2030 as Long-Term Contracts Cover Over Half of 2027 Capacity
Tokening, RenderCache, and Selectivity Make Software Claims Easier to Inspect
Quantum Art Wave Simulation Claim Raises the Question of What a Quantum Result Actually Delivers
AI Infrastructure Financing Digest October 22 2026 Shows Short Debt Funding Long Bets
CrossGov's Overlooked Federal Numbers: $13.5 Million Saved on $1 Billion, a 14% Sustain Rate and a 60-Year-Old System Still Running
Press Release Digest: Rubrik Puts Claude Mythos 5 on Code Security, Factory Hits $5 Billion, TeRAM Takes On the AI Memory Wall
Vicor Fiscal 2025 10-K Adds New AI Demand Risk
OFAC Adds 24 Names to the SDN List in Narcotics and Organized Crime and Cyber Actions, November 19, 2026
China Commerce Ministry Reports Stable Double Eleven Consumption Trends
BIS Export Control Rule, Addressing Remote Access to Advanced Semiconductors, November 19, 2026
OFAC Adds 6 Names to the SDN List in Counterterrorism Actions, November 18, 2026
South Korea Policy Briefing Posts Outline Content Restrictions
Lumentum Fiscal 2026 10-K Adds New Intellectual Property Risks
Insider Trades at Chip and AI Infrastructure Companies, November 18, 2026
CISA Adds 4 Exploited Vulnerabilities in Synology, BerriAI and Others Products, November 18, 2026
NVIDIA Guides Fiscal Q4 2027 Revenue to $130 Billion, Up 12 Percent From Fiscal Q3 2027

Copyright © 2026 PressMediaRelease.com

Media Partners: Technologies · Market Analysis · Market Research · Photography · Media Presser · 3V · Briefly · ESN